All News

Study finds rural Appalachia faces soaring insomnia and sleep apnea, tied to poverty and stress, urging targeted, equity-focused sleep interventions.

Steven Daveluy, MD, discusses 3-year findings that show 86% of patients remained HS flare-free throughout treatment, reinforcing the case for early intervention.

A real-world study has found that personalizing ibrutinib doses based on patient health does not compromise survival outcomes in chronic lymphocytic leukemia (CLL).

Major health plans cut millions of preapproval hurdles, add 90-day continuity protections, and push real-time e-authorization to speed care access.

A 2026 survey finds 2 in 3 employed adults would be more likely to use GLP-1 weight-loss drugs if employer coverage or behavioral support programs were available.

Both Quantitative Myasthenia Gravis and Myasthenia Gravis Activities of Daily Living scores improved after treatment.

Experts outline 4 roles within the value-based care ecosystem that will make it more cohesive and effective for patients.

Ultrasound AI models use radiomics and deep learning to predict DLBCL survival, enabling low-cost, noninvasive risk stratification.

Despite a 24% drop since 2015, over 4 million Americans remain on long-term opioids, and they’re older, on Medicare, and increasingly coprescribed risky drugs.

Phase 3 CANOPY data show pemivibart safely prevented COVID-19 in patients with CLL, supporting EUA use for immunocompromised populations.

Posttransplant gilteritinib maintenance therapy may boost survival and reduce relapse in relapsed FLT3-mutated acute myeloid leukemia (AML), but larger trials are still needed.

Repeated at-home stool DNA screening shows higher real-world adherence than colonoscopy, boosting early colorectal cancer detection and cutting deaths over 10 years.

Manufacturer-sponsored biologic coupons have decreased since 2018, with rising per-claim values, impacting patient costs and formulary incentives.

Poor outcomes could be predicted based on the presence of ectopic germinal centers in the thymus in patients with thymoma-associated myasthenia gravis.

Social determinants of health can delay access to NGS, limiting targeted therapy use and survival outcomes in advanced cancers.

Sequential therapy of ranibizumab and a dexamethasone implant improved results in macular edema secondary to non–ischemic retinal vein occlusion.

JoAnn Manson, MD, shares findings from the VIVID trial on vitamin D, the timing of use, and its potential to reduce long COVID risk and symptom severity.

ACIP changes threaten vaccine coverage and raise costs, according to a roundtable of experts warning of widening disparities and long-term public health risks.

New evidence affirms hepatitis B birth-dose safety as the CDC makes it optional.

Strength and aerobic training improves cardiorespiratory fitness, functional capacity, and muscle strength more than aerobic exercise alone in heart failure.

Global pediatric HIV data show dolutegravir links to early modest weight gain that plateaus by year 2, easing concerns and highlighting regional nutrition gaps.

Despite decreases in therapy use, hospitalizations for multiple sclerosis and neurologist visits were not affected significantly.

A study suggests vitamin D may reduce long COVID symptoms at 8 weeks, although larger trials are needed to confirm benefits and optimal timing, explains JoAnn E. Manson, MD, MPH, DrPH.

The cap cut quarterly spending by the hundreds and lowered A1c levels but failed to expand the pool of insulin users.

MASH can have a significant impact on patients’ quality of life, particularly if they have comorbidities or advanced fibrosis.

From teledermatology billing to rural outreach and transplant advances, new studies and presentations reveal shifts in access, equity, and patient outcomes.

Proactive adverse effect management helps patients with skin cancer stay on treatment longer, according to Todd Schlesinger, MD.

A new study suggests that incorporating proteomic data can help refine risk stratification in mantle cell lymphoma (MCL).